Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Subcutaneous Pegfilgrastim in Healthy Men
NCT04873765Phase 1Completed
- Sponsor
- Megalabs
- Start
- Mar 2022
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of pegfilgrastim in neutropenia (2 arms), sponsored by Megalabs. Primary endpoints: Maximum Plasma Concentration at 16 days, Area Under the Curve from time 0 to last measurable concentration at 16 days and 1 more. Started Mar 2022; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04873765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873765.